Corby Fink1, Michael Smith1, Jeffrey M Gaudet2, Ashley Makela2, Paula J Foster2, Gregory A Dekaban3. 1. Molecular Medicine Research Laboratories, Robarts Research Institute and Department of Microbiology and Immunology, University of Western Ontario, 1151 Richmond Street North, London, Ontario, N6A 5B7, Canada. 2. Imaging Research Laboratories, Robarts Research Institute and Department of Medical Biophysics, University of Western Ontario, 1151 Richmond Street North, London, Ontario, N6A 5B7, Canada. 3. Molecular Medicine Research Laboratories, Robarts Research Institute and Department of Microbiology and Immunology, University of Western Ontario, 1151 Richmond Street North, London, Ontario, N6A 5B7, Canada. dekaban@robarts.ca.
Abstract
PURPOSE: A major hurdle in the advancement of cell-based cancer immunotherapies is the inability to track in vivo therapeutic cell migration. With respect to dendritic cell (DC)-based cancer immunotherapies, this lack of knowledge represents an even greater hurdle as the quantity of tumor-antigen specific DC reaching a secondary lymphoid organ post injection is predictive of the magnitude of the ensuing tumor-specific immune response. We propose fluorine-19 (F-19) cellular magnetic resonance imaging (MRI) as a suitable and non-invasive imaging modality capable of detecting and quantifying DC migration in vivo and thus, serving as a surrogate marker of DC-based immunotherapeutic effectiveness. PROCEDURES: Murine DC were generated from bone marrow precursors and labeled with a [19F]perfluorocarbon ([19F]PFC)-based cell labeling agent. DC were characterized by viability and phenotyping assessments as well as characterized by ability to induce in vivo tumor-specific immune responses following immunization in a B16-F10 mouse model of melanoma. The in vivo migration of [19F]PFC (PFC)-labeled DC was first compared to control unlabeled DC by microscopy and then measured using F-19 cellular MRI. RESULTS: Culture conditions were optimized such that > 90 % of DC labeled with PFC without affecting viability, phenotype, and function. This optimization permitted consistent detection of PFC-labeled DC migration using F-19 cellular MRI and resulted in the first successful comparison of in vivo migration between PFC-labeled and control unlabeled therapeutic cells of the same origin. PFC-labeled DC are migration-competent in vivo in a B16-F10 tumor-bearing mouse model. CONCLUSIONS: We report a non-invasive and longitudinal imaging modality capable of detecting and quantifying therapeutic cell migration at both 9.4 and 3 Tesla (T) and suitable for therapeutic cell tracking in a tumor-bearing mouse model. F-19 MRI cell tracking is broadly applicable across disease states and is conducive to clinical translation.
PURPOSE: A major hurdle in the advancement of cell-based cancer immunotherapies is the inability to track in vivo therapeutic cell migration. With respect to dendritic cell (DC)-based cancer immunotherapies, this lack of knowledge represents an even greater hurdle as the quantity of tumor-antigen specific DC reaching a secondary lymphoid organ post injection is predictive of the magnitude of the ensuing tumor-specific immune response. We propose fluorine-19 (F-19) cellular magnetic resonance imaging (MRI) as a suitable and non-invasive imaging modality capable of detecting and quantifying DC migration in vivo and thus, serving as a surrogate marker of DC-based immunotherapeutic effectiveness. PROCEDURES: Murine DC were generated from bone marrow precursors and labeled with a [19F]perfluorocarbon ([19F]PFC)-based cell labeling agent. DC were characterized by viability and phenotyping assessments as well as characterized by ability to induce in vivo tumor-specific immune responses following immunization in a B16-F10 mouse model of melanoma. The in vivo migration of [19F]PFC (PFC)-labeled DC was first compared to control unlabeled DC by microscopy and then measured using F-19 cellular MRI. RESULTS: Culture conditions were optimized such that > 90 % of DC labeled with PFC without affecting viability, phenotype, and function. This optimization permitted consistent detection of PFC-labeled DC migration using F-19 cellular MRI and resulted in the first successful comparison of in vivo migration between PFC-labeled and control unlabeled therapeutic cells of the same origin. PFC-labeled DC are migration-competent in vivo in a B16-F10 tumor-bearing mouse model. CONCLUSIONS: We report a non-invasive and longitudinal imaging modality capable of detecting and quantifying therapeutic cell migration at both 9.4 and 3 Tesla (T) and suitable for therapeutic cell tracking in a tumor-bearing mouse model. F-19 MRI cell tracking is broadly applicable across disease states and is conducive to clinical translation.
Entities:
Keywords:
Cancer immunotherapy; Cellular magnetic resonance imaging (MRI); Dendritic cell (DC); Fluorine-19 (F-19)
Authors: Pauline Verdijk; Erik H J G Aarntzen; W Joost Lesterhuis; A C Inge Boullart; Ellemieke Kok; Michelle M van Rossum; Simon Strijk; Femke Eijckeler; Johannes J Bonenkamp; Joannes F M Jacobs; Willeke Blokx; J Han J M Vankrieken; Irma Joosten; Otto C Boerman; Wim J G Oyen; Gosse Adema; Cornelis J A Punt; Carl G Figdor; I Jolanda M de Vries Journal: Clin Cancer Res Date: 2009-03-24 Impact factor: 12.531
Authors: Gerty Schreibelt; Daniel Benitez-Ribas; Danita Schuurhuis; Annechien J A Lambeck; Maaike van Hout-Kuijer; Niels Schaft; Cornelis J A Punt; Carl G Figdor; Gosse J Adema; I Jolanda M de Vries Journal: Blood Date: 2010-04-27 Impact factor: 22.113
Authors: Elizabeth Scheid; Pierre Major; Alain Bergeron; Olivera J Finn; Russell D Salter; Robin Eady; Bader Yassine-Diab; David Favre; Yoav Peretz; Claire Landry; Sebastien Hotte; Som D Mukherjee; Gregory A Dekaban; Corby Fink; Paula J Foster; Jeffery Gaudet; Jean Gariepy; Rafick-Pierre Sekaly; Louis Lacombe; Yves Fradet; Ronan Foley Journal: Cancer Immunol Res Date: 2016-09-07 Impact factor: 11.151
Authors: Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield Journal: Oncoimmunology Date: 2012-05-01 Impact factor: 8.110
Authors: Alfonso MartIn-Fontecha; Silvia Sebastiani; Uta E Höpken; Mariagrazia Uguccioni; Martin Lipp; Antonio Lanzavecchia; Federica Sallusto Journal: J Exp Med Date: 2003-08-18 Impact factor: 14.307
Authors: Julia J Gevaert; Corby Fink; Jimmy D Dikeakos; Gregory A Dekaban; Paula J Foster Journal: Mol Imaging Biol Date: 2022-06-01 Impact factor: 3.488
Authors: Fiona Cooke; Mary Neal; Matthew J Wood; I Jolanda M de Vries; Amy E Anderson; Julie Diboll; Arthur G Pratt; James Stanway; Ioana Nicorescu; Nicholas Moyse; Dawn Hiles; David Caulfield; Anne M Dickinson; Andrew M Blamire; Pete Thelwall; John D Isaacs; Catharien M U Hilkens Journal: Front Immunol Date: 2022-10-03 Impact factor: 8.786